The World Health Organization estimates that one million new pediatric tuberculosis cases and 59 194,000 childhood deaths from the disease occurred in 2017 (1). Rapid case detection and 60 treatment initiation is critical to minimizing TB morbidity and mortality in children but is 61 hampered by the absence of a rapid, accurate diagnostic tool in this group. Bacteriologic 62 confirmation of Mycobacterium tuberculosis (Mtb) in children is often difficult to achieve 63 because they are frequently unable to expectorate sputum for bacteriologic testing and often have 64 paucibacillary disease that cannot be detected using sputum smear microscopy, culture, and/or 65 molecular testing [e.g. Xpert (Cepheid, Sunnyvale CA, USA)]. Sputum induction and gastric 66 aspiration are two procedures that can be used to obtain respiratory specimens from children 67 unable to expectorate sputum; however, gastric aspiration is invasive and neither procedure is 68 widely implemented in resource-constrained settings. Due to these diagnostic challenges, 4 bacteriologic confirmation of TB is obtained in only a small minority of children diagnosed with 70 TB in resource-limited clinical settings (2-4). 71
72
Stool is a sample type that can be easily obtained from most children, and from which Mtb can 73 be detected using Xpert (5-10) or other laboratory-developed PCR assays (11-13). However, 74 isolation and amplification of DNA using extraction kits and in-house tests is an often laborious, 75 multistep procedure. In the case of Xpert, the process is automated, but detection of drug 76 resistance is currently limited to rifampin-associated resistance mutations in rpoB. An ideal test 77 would be an automated point-of-care workstation with integrated capacity for both Mtb and 78 expanded drug resistance testing -criteria listed in the product profile for novel TB diagnostics in 79 low resource settings (14). The TruTip workstation is a multiplex automated platform for nucleic 80 acid extraction (Akonni Biosystems, Frederick, MD, USA) (15,16). The platform can be 81 connected to a closed amplicon system for amplification and microarray-based detection of Mtb 82 as well as a number of drug resistance-associated mutations (17) (18) (19) Between May 2015 and February 2018, we consecutively recruited children to participate in a 97 pediatric TB diagnostics study. Eligible children were less than 15 years of age, had a history of 98 contact with an adult with TB in the last two years, and presented to a participating public sector 99 health center in Lima, Peru with symptoms compatible with TB (i.e., persistent cough for more 100 than two weeks; unexplained weight loss; unexplained fever for more than one week; and/or 101 unexplained fatigue or lethargy) (21). For this analysis, we included the subset of children with 102 culture-confirmed TB or clinically-diagnosed unconfirmed TB who had at least one stool sample 103 available. We also included a subset of the children in whom TB had been ruled out (i.e, 104 controls), matching on age and sample collection date when possible. 105 6 chain transported to the laboratory and stored at -80°C until testing. Because testing of stool did 116 not occur in real time and because the assay was experimental, stool testing results were not 117 shared with families or healthcare providers. HIV testing was not performed because the HIV 118 prevalence among children in the study setting is <0.1% (23) . replicates was <37 and the change in fluorescence was >6 units. We repeated the PCR step in 136 duplicate for discordant replicates and considered the sample to be indeterminate for Mtb DNA if 7 the two replicates remained discrepant after a second PCR run. Laboratory staff were blinded to 138 participants' clinical and demographic information. 139 child-level (including all samples from each child) and at the sample-level. We calculated 144 sensitivity and specificity and 95% confidence intervals (CI). Sensitivity of Mtb detection from 145 stool was calculated separately for children with confirmed TB (i.e., based on a positive culture 146 from sputum or GA) and clinically-diagnosed unconfirmed TB. Specificity was calculated 147 among those in whom TB had been ruled out. Among children with TB, we conducted chi-148 square tests to examine the associations between a positive stool test and the following variables: 149 age, sex, smear and culture results, and cavitation on chest x-ray. A p-value of <0.05 was 150 considered statistically significant. Numerical precision for all percentages, p-values and 95% 151
CIs is presented based on the evidence-based recommendations proposed by Cole (25) . with culture-confirmed TB and 84 children with unconfirmed, clinically diagnosed TB (Fig 1) . 162
Children between the ages of 11 and 14 years old were more likely to have a culture-confirmed 163 diagnosis, and all seven children with smear-positive sputum belonged to this older age group 164 ( 
Per child analyses 196
In child-level analyses sensitivity of the stool assay was 55% (95% CI: 33%-75%) in the 197 confirmed TB cases based on the results of each child's first sample. Analyzing both sample 1 0 results led to identification of one additional confirmed TB case and a sensitivity of 59% (95% 199 CI: 39%-80%) ( Table 3) more common in the 11-14 year age group (Fig 2; Table 4 ). There was no association between 213 stool positivity and sex. 214 215 Importantly, we detected Mtb in stool of three children below the age of five that were not able 224 to expectorate sputum (two of whom were diagnosed based on GA samples and one who was 225 clinically diagnosed). The overall sensitivity (59%) and specificity (97%) of this assay relative to 1 2 liquid culture of respiratory samples was comparable to previous pediatric studies using Xpert 227 for stool testing (7,26). Moreover, it is comparable to the 62% estimated sensitivity of Xpert for 228 pediatric sputum samples compared to culture (27) . Unfortunately, similar to other studies (6,28-229 30), we rarely detected TB in children with culture negative, clinically diagnosed TB. 230
231
In line with previous reports (8,31) we found strong associations between a positive stool test 232 and signs of more adult-like TB (i.e., cavitary disease; positive sputum culture; positive sputum 233 smear; the ability to produce sputum), which were most common in the oldest age group. In our 234 study, in contrast to DiNardo et al (12), there was no negative association between stool 235 positivity and collection of stool > 72 hours post treatment initiation, which likely was related to 236 the fact that late collection often occurred among (older) children with smear-positive respiratory 237 samples. This emphasizes the impact of age and smear status on the outcomes of stool testing. 238
This has critical implications for the reporting of pediatric TB diagnostic studies because stool 239 assay sensitivities may vary widely based on the percentage of children in the cohort with adult-240 like TB and/or high bacterial burden. Because children with adult-like TB are often able to 241 produce a sputum sample for testing, a stool assay will only begin to fill the pediatric TB 242 diagnostic gap if it is sensitive in children who cannot already spontaneously expectorate 243 sputum. To facilitate an understanding of stool assay performance and its utility across settings, 244 we recommend stratifying stool sensitivity results by some measure of disease severity, ideally 245 smear status, and reporting results according to whether the child was able to spontaneously 246 expectorate sputum. 247 1 3
The TruTip workstation had a number of attractive attributes for Mtb DNA extraction from stool. 249
Extraction procedures required limited pipetting steps and transfer of larger volumes compared 250 to commercially available kits, even though in the present study the TruTip workstation was not 251 yet in its final automated (sample-to-answer) form. Eventually, the TruTip will be integrated 252 with a microarray-based detection of Mtb as well as a number of drug resistance-associated 253 mutations (17-19), and additionally it will have the advantage that the extracted DNA eluate can 254 be isolated for other purposes, such as sequencing. It was a limitation that we had no access yet 255 to the fully automated TruTip workstation here, and could not evaluate its use. Another 256 limitation in our study was that we had no follow-up data for the children in the control group, Acknowledgements 290
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